Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data

  title={Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data},
  author={Lucilla Parnetti and Francesco Amenta and Virgilio Gallai†},
  journal={Mechanisms of Ageing and Development},

Tables from this paper

Choline alphoscerate pharmacology and its role in the treatment of cognitive impairment related to neurological disorders
Preliminary evaluations suggest a useful role for choline alphoscerate in patients with cognitive impairment of varying severity related to brain trauma or to Parkinson’s disease, and literature data suggest that, in these conditions, the semi-synthetic compound shows a better efficacy than other cholinergic precursors and has a good tolerability and safety profile.
Treatment of dementia with neurotransmission modulation
The prevalence of dementia is growing in developed countries where elderly patients are increasing in numbers. Neurotransmission modulation is one approach to the treatment of dementia. Cholinergic
The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: interim results after two years of treatment.
Findings suggest that the combination of choline alphoscerate with a ChE-I may prolong/increase the effectiveness of cholinergic therapies in AD with concomitant ischemic cerebrovascular injury.
Prospects Of Pharmacological Treatment Of Vascular Dementia In Patients With Arterial Hypertension
A reliable nootropic effect of the drug was revealed, as well as its effect on cerebrosthenic and somatovegetative manifestations.
Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review
From the data reported in the literature, it emerges that nootropics may be an effective alternative for strengthening and enhancing cognitive performance in patients with a range of pathologies.
Volume Analysis of Brain Cognitive Areas in Alzheimer’s Disease: Interim 3-Year Results from the ASCOMALVA Trial
The findings indicate that the addition of choline alphoscerate to standard treatment with the cholinesterase inhibitor donepezil counters to some extent the loss in volume occurring in some brain areas of AD patients.


Failure of long term high-dose lecithin to retard progression of early-onset Alzheimer's disease.
It appears that lecithin alone has no important therapeutic effect in early-onset Alzheimer's disease.
Lecithin and memory training in suspected Alzheimer's disease.
Following-up trials of memory training under placebo and lecithin conditions provided some suggestion that memory training may lead to some immediate improvement in list-learning ability, but the improvement was not well maintained overtime.
Brain neurotransmitters in aging and dementia: similar changes across diagnostic dementia groups.
The data underline the difficulties in drawing clear demarcation lines between normal and pathological aging and between different subgroups of dementia.
The cholinergic system in Alzheimer's disease
Alzheimer's disease is an overwhelming and frequently unmanageable burden on the national medical and nursing home budget, and one of the reasons why so much research in recent years has been invested in the elucidation of the etiology and pathophysiology of Alzheimer's disease.
Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study.
A multicenter double-blind placebo-controlled study of cytidine 5'-diphosphocholine (CDP-choline) was conducted to evaluate possible clinical benefits of the drug in patients with acute, moderate to severe cerebral infarction, and CDP- choline showed significant improvements in level of consciousness compared with the placebo-treated group.
A Multicentre Trial to Evaluate the Efficacy and Tolerability of α-Glycerylphosphorylcholine versus Cytosine Diphosphocholine in Patients with Vascular Dementia
The results suggest that in most tests α-GPC possessed a statistical higher efficacy and an overall more satisfactory activity assessed by both patients and investigators compared with CDP.
α‐Glycerophosphocholine in the Mental Recovery of Cerebral Ischemic Attacks
The clinical efficacy and the tolerability of alpha-glycerophosphocholine (alpha-GPC), a drug able to provide high levels of choline for the nervous cells of the brain and to protect their cell
Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain.
Demonstration of selective degeneration of neurons of the nucleus basalis of Meynert represents the first documentation of a loss of a transmitter-specific neuronal population in a major disorder of higher cortical function and points to a critical subcortical lesion in Alzheimer's patients.